Quince Therapeutics, Inc. Convertible Notes Payable
Quince Therapeutics, Inc. (QNCX) had Convertible Notes Payable of $8.00 million as of 2019-01-31, per its 10-K filed 2021-03-01.
Discontinued › Balance Sheet › Liabilities › Debt
us-gaap:ConvertibleNotesPayable · last filed 2021-03-01
- 2019-01-31: Convertible Notes Payable $8.00M.
| Period end | Convertible Notes Payable |
|---|---|
| 2019-01-31 | $8.00M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |